| Name | Title | Contact Details |
|---|
Genus is a world-leading animal genetics company. At the forefront of innovation in gene-editing, advanced reproductive biology, and other breakthrough breeding technologies, Genus R&D advances an agricultural practice thousands of years old – animal breeding. Our goal is to ensure the global food system continues to nurture healthy, productive animals that yield affordable, high-quality proteins for a sustainable future. We believe a more sustainable food system starts with better breeding and genetics. Through ABS Global (bovine) and PIC (porcine), we supply high-quality breeding animals with desirable characteristics to farmers, enabling them to produce better quality meat and milk more efficiently to feed the world more sustainably. Our breeding animals desirable characteristics include feed efficiency, disease resistance, growth rate, protein and fat content, and fertility. ABS Global is the world-leading provider of bovine genetics, reproduction services, technologies, and udder care products. Marketing in more than 70 countries around the globe, ABS has been at the forefront of animal genetics and technology since its founding in 1941. In bovine genetics, ABS serves more than 40,000 customers globally, including some of the worlds leading beef and dairy producers. PIC, which stands for ‘Pig Improvement Company, was founded in 1962 in Oxfordshire, England. PIC strives to make their customers the most successful pig producers in the world and their "Never Stop Improving" philosophy means a continuous effort to listen carefully to customers and drive innovation to create ever-increasing value for pig and pork producers.
One Stop Label Corp is a Ontario, CA-based company in the Business Services sector.
Hillside Party Ctr is a Cleveland, OH-based company in the Business Services sector.
We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)